Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-05-24 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
F-3ASR
Regulatory Filings Classification · 95% confidence The document is a Form F-3 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) by AstraZeneca PLC and AstraZeneca Finance LLC. It is a registration statement under the Securities Act of 1933 for the offering of debt securities. The document includes a prospectus describing the securities, risk factors, company information, and legal disclaimers. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to capital markets and securities registration. Given the nature of the document as a registration statement and prospectus, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories like Annual Report, Earnings Release, or Capital/Financing Update. The document is lengthy (15,000 characters) and contains detailed legal and offering information, not just an announcement or notice, so it is not a Report Publication Announcement (RPA). Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-05-24 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to SEC rules. It contains unaudited pro forma condensed combined financial information related to the merger of AstraZeneca and Alexion Pharmaceuticals, including income statements and statements of financial position. The document includes detailed financial data and notes, indicating it is a substantive financial report rather than a mere announcement or certification. The presence of pro forma financials related to a merger suggests it is related to merger activity, but the document is primarily focused on financial information and pro forma combined financial statements. Given the detailed financial data and the nature of the filing (Form 6-K with pro forma financials), the best fitting category is Interim / Quarterly Report (IR), as it contains comprehensive financial data for a period shorter than a full fiscal year and is not a full annual report (10-K) or a merger proxy statement (MA). It is not a simple announcement or regulatory filing. Confidence is high due to the detailed financial content and the nature of the Form 6-K pro forma financial information.
2021-05-24 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed by AstraZeneca PLC pursuant to Rule 425 under the US Securities Act of 1933, which is a rule related to merger communications. It references the proposed acquisition of Alexion Pharmaceuticals, including details about proxy statements, registration statements (Form F-4), and solicitation of proxies. The document discusses competition clearances, forward-looking statements about the acquisition, and provides information on where to obtain related SEC filings. The presence of Rule 425 filing and the focus on acquisition-related communications indicate this is a merger communication filing. It is not a full merger proxy statement or tender offer filing (which would be classified as MA), but a communication related to the merger process under Rule 425. According to the filing definitions, this corresponds to Merger & Acquisition (MA) activity filings, which include Form 425 merger communications. The document length is sufficient and contains substantive information about the acquisition process, not just an announcement or a certification. Therefore, the correct classification is MA with high confidence.
2021-05-24 English
ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It announces the emergency use authorization of AstraZeneca's COVID-19 vaccine Vaxzevria in Japan. The content is primarily an announcement of a regulatory approval and related information, not a detailed financial report or earnings release. The document length is 5711 characters, which is relatively short and the content is focused on a specific event rather than comprehensive financial data or management discussion. There is no indication of financial statements, audit information, or detailed management analysis. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as earnings release, annual report, or capital update.
2021-05-21 English
Vaxzevria COVID-19 vaccine approved in Japan
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 4137Z' and is dated '21 May 2021'. It contains a headline about a regulatory action ('AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan') and concludes with standard boilerplate text from 'RNS, the news service of the London Stock Exchange' stating that 'RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure is characteristic of a general regulatory announcement disseminated via the RNS system, which serves as the primary channel for official news releases on the LSE. Since the content is a specific announcement (vaccine authorization) and not a comprehensive report (like 10-K or IR), and it fits the description of a general regulatory filing that doesn't map to a more specific category like DIV, DIRS, or ER, the most appropriate classification is Regulatory Filings (RNS). The document length (5140 chars) is substantial enough that it is the announcement itself, not just a brief notice about an attachment.
2021-05-21 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC. It reports a transaction involving a director (Pascal Soriot, CEO) receiving a share award under the AstraZeneca Performance Share Plan. The content focuses on a director's shareholding transaction, detailing the number of shares granted, price, and related performance conditions. There is no financial performance data, earnings information, or management discussion. The document is a notification of a personal share transaction by a company director, which fits the definition of Director's Dealing (DIRS). The document length is about 5242 characters, sufficient to contain detailed transaction information rather than a brief announcement. Therefore, the correct classification is DIRS with high confidence.
2021-05-18 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.